Klivira
Request demo

Navigating Medicare Keytruda Prior Authorization

Klivira automates the complex process of securing **Medicare Keytruda prior authorization**, ensuring your oncology practice maintains compliance and optimizes revenue cycles.

For oncology practices, managing prior authorizations for high-cost, high-volume biologics like Keytruda (pembrolizumab) is critical. While Original Medicare's PA scope is limited, understanding its specific requirements and those of Medicare Advantage plans is essential to prevent claim denials and administrative burdens.

Keytruda (Pembrolizumab) and Medicare Coverage Considerations

Keytruda, a programmed death receptor-1 (PD-1) blocking antibody, is a high-volume immunotherapy used across various oncology indications. Coverage for pembrolizumab for Medicare beneficiaries typically falls under Medicare Part B (medical benefit) for infusions administered in a clinical setting, or Medicare Part D (pharmacy benefit) for self-administered forms, depending on the specific plan and indication. Adherence to National Coverage Determinations (NCDs) and Local Coverage Determinations (LCDs) is paramount for demonstrating medical necessity.

Original Medicare Prior Authorization for Keytruda

Original Medicare (Parts A and B) has a limited scope for prior authorization compared to commercial plans or Medicare Advantage. Where PA is required for Keytruda, such as for specific outpatient department services or certain durable medical equipment (DME), submissions route through the responsible Medicare Administrative Contractor (MAC) for the provider's jurisdiction. Klivira's platform is engineered for MAC-aware routing, handling per-jurisdiction submission specifics.

Key Medicare Administrative Contractors (MACs) Handling Original Medicare PA

  • Noridian
  • NGS
  • WPS
  • Palmetto
  • FCSO
  • Novitas

Medicare Advantage and Part D Prior Authorization for Keytruda

Medicare Advantage (MA) plans, operated by private insurers, often have broader prior authorization requirements for Keytruda, similar to commercial payer policies. For Keytruda covered under Medicare Part D, PA is administered by the individual Part D plans per their CMS-approved formularies and step-therapy protocols. Klivira integrates with these diverse payer portals and ePA channels to streamline submissions for both MA and Part D plans.

Policy Adherence: NCDs and LCDs for Keytruda Coverage

For Keytruda, medical necessity is primarily evaluated against CMS-published National Coverage Determinations (NCDs) and Local Coverage Determinations (LCDs) issued by the responsible MAC for each jurisdiction. Klivira's platform incorporates NCD/LCD-aware policy logic, ensuring that prior authorization requests are aligned with the latest coverage criteria, citing the specific NCD number or LCD ID, MAC jurisdiction, and effective date as required.

Streamlining Medicare Keytruda PA with Klivira

Klivira optimizes the prior authorization workflow for Keytruda across the Medicare landscape. Our platform automates submission channel identification, routes requests to the correct MACs for Original Medicare, and navigates the varied requirements of Medicare Advantage and Part D plans. By integrating NCD/LCD policy logic and connecting to relevant payer portals, Klivira reduces manual effort and accelerates approval times for this critical oncology medication.

Frequently asked questions

Does Original Medicare always require prior authorization for Keytruda?

No, Original Medicare's prior authorization scope is limited. While most services do not require PA, specific programs, such as for certain outpatient department services, may trigger a requirement. When PA is needed, it is routed through the relevant Medicare Administrative Contractor (MAC).

How do Medicare Advantage plans handle Keytruda prior authorization differently?

Medicare Advantage (MA) plans, as private insurance, typically have more extensive prior authorization requirements than Original Medicare. These plans often follow their own medical policies and formularies, which may include step-therapy protocols, similar to commercial payers. Klivira's system adapts to these diverse MA plan requirements.

What role do NCDs and LCDs play in Keytruda coverage under Medicare?

National Coverage Determinations (NCDs) from CMS and Local Coverage Determinations (LCDs) from MACs define the medical necessity criteria for Keytruda. Adherence to these published policies is crucial for prior authorization approvals, as they dictate specific indications, dosing, and patient populations for which Keytruda is covered under Medicare.

Is Keytruda typically covered under Medicare Part B or Part D?

Keytruda (pembrolizumab) is primarily covered under Medicare Part B when administered intravenously in a clinical setting, as it is considered a medical benefit. If there were a self-administered form, it would typically fall under Medicare Part D (pharmacy benefit), administered by private Part D plans according to their formularies.

How does Klivira support prior authorization for Keytruda with different Medicare plans?

Klivira streamlines Keytruda prior authorization by identifying the correct submission channel, whether it's a MAC for Original Medicare or a specific payer portal for Medicare Advantage or Part D plans. Our platform integrates NCD/LCD policy logic and automates data submission, reducing administrative burden and improving approval rates.

Related coverage

Other keytruda prior authorization by payer

Other keytruda prior authorization by specialty

Ready to automate prior auth for this drug?

See how Klivira automates prior authorizations for your team.

Request a demo